Boyd Watterson Asset Management LLC OH Has $4.06 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Boyd Watterson Asset Management LLC OH boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,047 shares of the company’s stock after acquiring an additional 1,261 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Boyd Watterson Asset Management LLC OH’s investment portfolio, making the stock its 21st largest holding. Boyd Watterson Asset Management LLC OH’s holdings in Johnson & Johnson were worth $4,059,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Beese Fulmer Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 0.5% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 125,084 shares of the company’s stock valued at $20,271,000 after buying an additional 679 shares during the period. Keene & Associates Inc. raised its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. Keene & Associates Inc. now owns 19,194 shares of the company’s stock worth $3,111,000 after acquiring an additional 131 shares in the last quarter. Global Assets Advisory LLC boosted its position in Johnson & Johnson by 9.4% during the third quarter. Global Assets Advisory LLC now owns 7,808 shares of the company’s stock valued at $1,265,000 after purchasing an additional 670 shares during the last quarter. X Square Capital LLC grew its stake in Johnson & Johnson by 3.1% in the third quarter. X Square Capital LLC now owns 5,890 shares of the company’s stock valued at $954,000 after purchasing an additional 179 shares in the last quarter. Finally, Franklin Parlapiano Turner & Welch LLC increased its position in Johnson & Johnson by 1.1% in the 3rd quarter. Franklin Parlapiano Turner & Welch LLC now owns 48,439 shares of the company’s stock worth $7,850,000 after purchasing an additional 548 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 1.3 %

Shares of JNJ stock opened at $163.67 on Friday. The stock has a 50 day moving average of $163.29 and a 200-day moving average of $154.92. The firm has a market cap of $393.90 billion, a PE ratio of 10.20, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted $2.66 EPS. On average, equities analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 30.92%.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. TD Cowen lowered their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Citigroup boosted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.93.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.